Immupharma PLC IMM RNS Posting of RA and Notice of AGM 30 June 23 (7207B)
06 June 2023 - 4:00PM
UK Regulatory
TIDMIMM
RNS Number : 7207B
Immupharma PLC
06 June 2023
RNS: RELEASE 6 June 2023
ImmuPharma PLC
("ImmuPharma" or the "Company")
Notice of AGM & Annual Report & Accounts
ImmuPharma PLC (LSE AIM: IMM), the specialist drug discovery and
development company, confirms that the Notice of Annual General
Meeting ("AGM") has today been posted to shareholders. The Annual
Report and Accounts for the year ended 31 December 2022 has also
been posted to shareholders today.
These documents will be available shortly, in electronic form,
for download on the Company's website www.immupharma.co.uk .
ImmuPharma's AGM will be held on Friday 30th June 2023 @ 11:00am
(BST) at: One Bartholomew Close, London, EC1A 7BL.
Ends
For further information please contact:
ImmuPharma PLC ( www.immupharma.com )
Tim McCarthy, Chairman and Chief Executive
Officer + 44 (0) 207 206 2650
Lisa Baderoon, Head of Investor Relations + 44 (0) 7721 413496
SPARK Advisory Partners Limited (NOMAD)
Neil Baldwin +44 (0) 203 36 8 3550
Stanford Capital Partners (Joint Broker)
Patrick Claridge, John Howes, Bob Pountney +44 (0) 203 815 8880
SI Capital (Joint Broker)
Nick Emerson +44 (0) 1483 413500
Notes to Editors
About ImmuPharma PLC
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical
company that discovers and develops peptide-based therapeutics. The
Company's portfolio includes novel peptide therapeutics for
autoimmune diseases and anti-infectives. The lead program, P140
(Lupuzor(TM)), is a first-in class autophagy immunomodulator for
the treatment of Lupus and preclinical analysis suggest therapeutic
activity for many other autoimmune diseases that share the same
autophagy mechanism of action.
For additional information about ImmuPharma please visit
www.immupharma.co.uk
ImmuPharma's LEI (Legal Entity Identifier) code:
213800VZKGHXC7VUS895
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NOAFLFETRDIEIIV
(END) Dow Jones Newswires
June 06, 2023 02:00 ET (06:00 GMT)
Immupharma (AQSE:IMM.GB)
Historical Stock Chart
From Nov 2024 to Dec 2024
Immupharma (AQSE:IMM.GB)
Historical Stock Chart
From Dec 2023 to Dec 2024
